McKesson (MCK) Stock Price, Quote, News & History | Benzinga

McKesson Corp (MCK) — Q4 FY26 Earnings Call Live coverage with Benzinga. Q4 FY26 Results EPS: $11.69 (est. $11.57) — inline Revenue: $96.30B (est. $101.49B) — inline Reported: 2026-05-07 Recent Quarters Q3 FY26 (2026-02-04): EPS $9.34 vs est $9.29 · Rev $106.16B vs est $105.81B Q2 FY26 (2025-11-05): EPS $9.86 vs est $9.00 · Rev $103.15B vs est $104.34B Q1 FY26 (2025-08-06): EPS $8.26 vs est $8.18 · Rev $97.83B vs est $96.23B Q4 FY25 (2025-05-08): EPS $10.12 vs est $9.83 · Rev $90.82B vs est $94.20B About McKesson Corp McKesson Corp is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the US pharmaceutical wholesale industry. Outside the US market, McKesson engages in pharmaceutical wholesale and distribution in Canada. https://www.mckesson.com · Irving, TX, USA · 51,000 employees Follow Benzinga X: https://x.com/Benzinga Facebook: https://www.facebook.com/Benzinga/ Instagram: https://www.instagram.com/benzinga/ ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes. #earnings #MCK #stocks #benzinga